MBIO Quote, Financials, Valuation and Earnings

Fortress Biotech has a net margin of -- compared to Mustang Bio's net margin of -87.96%. Mustang Bio's return on equity of -- beat Fortress Biotech's return on equity of --.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 7362.69%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 922.22%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.825, suggesting its more volatile than the S&P 500 by 82.547%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $14.6M. Mustang Bio's net income of -$1.4M is higher than Fortress Biotech's net income of -$12.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.42x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Mustang Bio's net margin of 35.65%. Mustang Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 7362.69%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 457.69%. Given that Mustang Bio has higher upside potential than Protalix BioTherapeutics, analysts believe Mustang Bio is more attractive than Protalix BioTherapeutics.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Mustang Bio's net income of -$1.4M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 86.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 4.04x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Mustang Bio's net margin of -18.58%. Mustang Bio's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 7362.69%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Mustang Bio has higher upside potential than Retractable Technologies, analysts believe Mustang Bio is more attractive than Retractable Technologies.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Mustang Bio's net income of -$1.4M is higher than Retractable Technologies's net income of -$1.9M. Notably, Mustang Bio's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Mustang Bio's net margin of -118.53%. Mustang Bio's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Mustang Bio has a consensus price target of --, signalling upside risk potential of 7362.69%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 151.4%. Given that Mustang Bio has higher upside potential than Stereotaxis, analysts believe Mustang Bio is more attractive than Stereotaxis.

Mustang Bio has a beta of 2.143, which suggesting that the stock is 114.262% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

Mustang Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mustang Bio pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Mustang Bio quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Mustang Bio's net income of -$1.4M is higher than Stereotaxis's net income of -$7.5M. Notably, Mustang Bio's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mustang Bio is -- versus 5.66x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.